Anti-HA antibody facilitates functions like immunoprecipitation, western blot, and indirect immunofluorescence to fight the influenza virus. According to the CDC, it is estimated that the influenza virus has resulted in approximately 35 million cases of illness between 2018 to 2019 in the U.S.
Request for a sample here @ https://www.persistencemarketresearch.com/samples/31875
Covid-19 pandemic has reduced and delayed physician visits and hospitalization rate and is expected to reduce the demand of anti-HA antibody for short-term. However, this is expected to balance in long term scenario and growth trends will remains positive for the next decade. Manufacturing and supply chain activities of anti-HA antibody market are expected to hamper due to nation-wide lockdown situation across the majority of countries in the world amid Covid-19 pandemic.
The rise in prevalence of influenza infections is expected to drive anti-HA antibody market growth. With an increase in research and development activities for the anti-HA antibody, the leading industry players are investing in the anti-HA antibody market. For instance, in March 2020 Duke Human Vaccine Institute was awarded US$400 million federal grants for consecutive seven years by National Institute of Allergy and Infectious Diseases (NAID) for development of universal flu vaccine.
Increasing awareness and treatment seeking rate of influenza infection are expected to boost anti-HA antibody market growth. Stringent regulatory requirements for approval of drugs can hinder anti-HA antibody market growth.
Ask for Table Of Content here @ https://www.persistencemarketresearch.com/toc/31875
Market Segmentation
| Based on the type of antibody |
|
| Based on the application |
|
| Based on the sales channel |
|
Key Players
Some key players contributing in anti-HA antibody market are F. Hoffmann-La Roche AG, Bayer AG, Novartis AG, Johnson & Johnson, Pfizer Inc., Merck & Co., Inc., Bristol Myers Squibb Company, Amgen Inc., AbbVie Pharmaceuticals, Eli Lilly and Company, Alexion Pharmaceuticals Inc., GlaxoSmithKline plc., Seattle Genetics, Sanofi S.A., Biogen Inc., AstraZeneca PLC and others.
Pre-Book Right Now for Exclusive Analyst Support @ https://www.persistencemarketresearch.com/checkout/31875
About Us:
Persistence Market Research is here to provide companies a one-stop solution with regards to bettering customer experience. It does engage in gathering appropriate feedback after getting through personalized customer interactions for adding value to customers’ experience by acting as the “missing” link between “customer relationships” and “business outcomes’. The best possible returns are assured therein.
Contact Us:
Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com
Website – https://www.persistencemarketresearch.com